Zoetis (ZTS) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Zoetis Inc. (ZTS) insider buying and selling: 3 purchases, 1 sale
87 Form 4 Table I transactions filed with the SEC by Zoetis Inc. insiders between 2025-09-16 and 2026-10-02 (15-month history): 3 open-market purchases and 1 sale, plus 83 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $2.5M by Peck Kristin C on 2026-02-17.
Zoetis insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Zoetis insiders filed 3 purchases worth $886k and 1 sale worth $2.5M on the open market. The net balance is on the sell side: $1.7M more sold than bought.
The biggest buyer was Damelio Frank A (Director): $501k in 1 purchase, out of 3 different buyers. The biggest seller was Peck Kristin C (Chief Executive Officer): $2.5M in 1 sale, the only seller.
The largest trade of the period was a sale of $2.5M on Feb 17, 2026, by Peck Kristin C (Chief Executive Officer), under a 10b5-1 plan. Form 4 on sec.gov (0001628280-26-008594).
The only sale carries the 10b5-1 plan flag on the Form 4: scheduled months ahead.
The last three months show 0 purchases and 0 sales, against 3 and 0 in the three before. The latest purchase is from May 13, 2026; the latest sale from Feb 17, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Zoetis has more sales than 5 of the other 58, ranks 43 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, Zoetis included.
The 20 most important trades
The 3 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 87 ZTS trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-05-13 | 2026-05-13 | Damelio Frank A | Director | $501k | P — Open-market purchaseForm 4 footnoteF1 The Price reported in Table I, Column 4 is the price at which these shares were purchased in a single transaction. | SEC |
| 2026-05-11 | 2026-05-12 | Mccallister Michael B | Director | $233k | P — Open-market purchase Indirect holding, through: By trust 2 Form 4 footnotesF1 The Price reported in Table I, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $77.72 to $77.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 Shares held in the Michael and Charlene McCallister Family Trust DTD 11/14/2014 Charlene G. McCallister & Mr. Michael B McCallister, TTEEs, for the benefit of the reporting person and the reporting person's spouse. | SEC |
| 2026-05-13 | 2026-05-13 | Bisaro Paul | Director | $152k | P — Open-market purchaseForm 4 footnoteF1 The Price reported in Table I, Column 4 is the price at which these shares were purchased in a single transaction. | SEC |
| 2026-02-17 | 2026-02-17 | Peck Kristin C | Chief Executive Officer | $2.5M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF2 The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.01 to $126.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.01 to $127.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-17 | 2026-02-17 | Peck Kristin C | Chief Executive Officer | $837k | M — Option exercise (scheduled 10b5-1)Form 4 footnoteF1 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025, including for the sale of up to 20,000 shares of Zoetis common stock between January 2, 2026 and February 18, 2026 upon the exercise of certain vested stock options that have an expiration date of February 18, 2026. | SEC |
| 2026-02-19 | 2026-02-23 | Peck Kristin C | Chief Executive Officer | $461k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-08 | 2026-02-10 | Peck Kristin C | Chief Executive Officer | $347k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Peck Kristin C | Chief Executive Officer | $244k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-19 | 2026-02-23 | Joseph Wetteny | Chief Financial Officer | $89k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-19 | 2026-02-23 | Parent Louise M | Director | $78k | J — Other transaction (explained in the filing)Form 4 footnoteF2 Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. | SEC |
| 2026-02-19 | 2026-02-23 | Brannan Jamie | Executive Vice President | $72k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-19 | 2026-02-23 | Broadhurst Vanessa | Director | $66k | J — Other transaction (explained in the filing)Form 4 footnoteF2 Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. | SEC |
| 2026-02-06 | 2026-02-10 | Joseph Wetteny | Chief Financial Officer | $66k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-03-31 | 2026-04-01 | Sarbaugh Keith | Executive Vice President | $62k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-08 | 2026-02-10 | Joseph Wetteny | Chief Financial Officer | $62k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-19 | 2026-02-23 | Hattersley Gavin | Director | $61k | J — Other transaction (explained in the filing)Form 4 footnoteF2 Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. | SEC |
| 2026-02-19 | 2026-02-23 | Mccallister Michael B | Director | $53k | J — Other transaction (explained in the filing)Form 4 footnoteF2 Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. | SEC |
| 2026-02-19 | 2026-02-23 | Leatherberry Antoinette Renee | Director | $52k | J — Other transaction (explained in the filing)Form 4 footnoteF2 Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. | SEC |
| 2026-02-19 | 2026-02-23 | Norden Gregory | Director | $52k | J — Other transaction (explained in the filing)Form 4 footnoteF2 Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. | SEC |
| 2026-02-19 | 2026-02-23 | Ashton Nicholas | Executive Vice President | $50k | F — Tax withholding (shares surrendered for taxes) | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 16, 2025 and Oct 2, 2026, Zoetis Inc. open-market activity adds up to 3 purchases worth $886k and 1 sale worth $2.5M. The net balance is $1.7M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Zoetis Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| M | Option exercise | 42 | $837k |
| F | Tax withholding (shares surrendered for taxes) | 31 | $1.9M |
| J | Other transaction (explained in the filing) | 6 | $361k |
| G | Gift | 4 | $0 |
| P | Open-market purchase | 3 | $886k |
| S | Open-market sale | 1 | $2.5M |
| Total | Everything filed in the period | 87 | $6.5M |
45 of the 87 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 20 distinct people or entities have filed Zoetis Inc. transactions: 3 bought on the open market and 1 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Peck Kristin C | Chief Executive Officer | 8 | — | $2.5M (1) | 2026-02-23 |
| Damelio Frank A | Director | 2 | $501k (1) | — | 2026-08-11 |
| Mccallister Michael B | Director | 4 | $233k (1) | — | 2026-06-11 |
| Bisaro Paul | Director | 2 | $152k (1) | — | 2026-05-13 |
| Esch Kevin | Executive Vice President | 8 | — | — | 2026-05-01 |
| Lagano Roxanne | Executive Vice President | 7 | — | — | 2026-02-23 |
| Ashton Nicholas | Executive Vice President | 6 | — | — | 2026-02-23 |
| Brannan Jamie | Executive Vice President | 6 | — | — | 2026-02-23 |
Shown here are the 8 who moved the most money, out of 20. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was May 2026: 3 purchases and 0 sales, worth $886k. 13 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 1 | $2.5M |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 3 | $886k | 0 | $0 |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Zoetis Inc. (ZTS) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
1 of the 1 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Zoetis's 3 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Oct 2, 2026, and a Form 4 arrives up to two business days after the trade.
11 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none. Code J on its own only says "other transaction": which one it is, if the filing explains it, is in its footnote.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.